Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MIR429 (microRNA 429)

Written2015-08Yaguang Xi, Hong Chang
Mitchell Cancer Institute, University of South Alabama, USA. xi@health.southalabama.edu; hchang@health.southalabama.edu

Abstract Review on MIR429, with data on RNA, and where it is implicated.

Keywords MIR429

(Note : for Links provided by Atlas : click)

Identity

Alias_namesMIRN429
Alias_symbol (synonym)hsa-mir-429
Other alias
HGNC (Hugo) MIR429
LocusID (NCBI) 554210
Atlas_Id 51154
Location 1p36.33  [Link to chromosome band 1p36]
Location_base_pair Starts at 1104385 and ends at 1104467 bp from pter ( according to hg19-Feb_2009)  [Mapping MIR429.png]
Note MicroRNA 429 belongs to microRNA 200 family. MicroRNA 200 family consists of five microRNAs, microRNA 200b, microRNA 200a, microRNA 429, microRNA 200c and microRNA 141. MicroRNA 200b, microRNA 200a and microRNA 429 were transcribed as a single ploycistronic transcript from chromosome 1. And microRNA 200 family were demonstrated important roles in EMT (epithelial-mesenchymal transition) progress.

DNA/RNA

 
Description microRNA 429 located in chromosome 1 and microRNA 429 was transcribed with microRNA 200b and microRNA 200a as a ploycistronic transcript. The putative transcription start site locates about 6129 bp upstream of the precursor of microRNA 429.
Transcription MiR-429 precursor: 5'-CGCCGGCCGAUGGGCGUCUUACCAGACAUGGUUAGACCUGGCCCUCUGUCUAAUACUGUCUGGUAAAACCGUCCAUCCGCUGC-3'
Mature miR-429: 5'-UAAUACUGUCUGGUAAAACCGU-3'
Pseudogene No pseudogene was found.

Protein

Note microRNAs are not translated into proteins.

Implicated in

Note
  
Entity Tumor cell proliferation
Note Abnormal expression of miR-200a was reported in various tumors, including human breast cancer, gastric carcinoma, endometrial adenocarcinoma, gliomas, and colorectal carcinoma. MiR-429 could inhibit cell growth and induce apoptosis by directly targeting ONECUT2 in colorectal carcinoma and targeting BCL2 in esophageal carcinoma (Sun, Shen et al. 2014). Also, MiR-429 could induce apoptosis and suppress invasion by targeting BCL2 and SP1 in esophageal carcinoma (Wang, Li et al. 2013). However, miR-429 was also showed its anti-apoptosis function in colorectal cancer by targeting SOX2 (Li, Du et al. 2013).
  
  
Entity Tumor cells invasion and cancer metastasis
Note Members of miR-200 family showed vital roles in tumor cells invasion and cancer metastasis. As to miR-429, studies demonstrated it could repress tumor cell invasion and cancer metastasis by targeting ONECUT2 and SP1 in different tumors (Sun, Shen et al. 2014; Wang, Li et al. 2013).
  
  
Entity Repression of epithelial-mesenchymal transition (EMT)
Note EMT is an important feature of tumor cells. Tumor cells underwent EMT showed more invasion and metastatic properties. Studies demonstrated members of miR-200 family could directly target ZEB1 and ZEB2 and could be regulated as a feedback loop during EMT. Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastasizing ovarian cancer cells (Chen, Wang et al. 2011). In colorectal carcinoma cells, miR-429 could regulate EMT-related markers such as ZEB2, Vimentin, SNAI2 (SLUG) and SNAI1 (SNAIL) by targeting ONECUT2 (Sun, Shen et al. 2014).
  
  
Entity Chemoresistance
Note Cancer stem cells showed highly resistance to chemotherapy which make relapse of tumor. It was found that over-expression of miR-429 could increase drug sensitivity in metastasizing ovarian (Wang, Mezencev et al. 2014). However, it was reported that miR-429 was highly expressed in hepatocellular carcinoma tissues and enrichment of miR-429 in liver tumour-initiating cells with EPCAM expression would contributed to hepatocyte self-renewal, malignant proliferation, chemoresistance and tumorigenicity (Li, Tang et al. 2014).
  

Bibliography

Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells
Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF
Gynecol Oncol 2011 Apr;121(1):200-5
PMID 21277012
 
MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2
Li J, Du L, Yang Y, Wang C, Liu H, Wang L, Zhang X, Li W, Zheng G, Dong Z
Cancer Lett 2013 Feb 1;329(1):84-90
PMID 23111103
 
Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4
Li L, Tang J, Zhang B, Yang W, LiuGao M, Wang R, Tan Y, Fan J, Chang Y, Fu J, Jiang F, Chen C, Yang Y, Gu J, Wu D, Guo L, Cao D, Li H, Cao G, Wu M, Zhang MQ, Chen L, Wang H
Gut 2015 Jan;64(1):156-67
PMID 24572141
 
MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma
Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X, Wu M
Mol Cell Biochem 2014 May;390(1-2):19-30
PMID 24402783
 
Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells
Wang L, Mezencev R, Svajdler M, Benigno BB, McDonald JF
Gynecol Oncol 2014 Jul;134(1):96-103
PMID 24802724
 
MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma
Wang Y, Li M, Zang W, Ma Y, Wang N, Li P, Wang T, Zhao G
Cell Oncol (Dordr) 2013 Oct;36(5):385-94
PMID 23999873
 

Citation

This paper should be referenced as such :
Xi Y, Chang H
MIR429 (microRNA 429);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Genes/MIR429ID51154ch1p36.html


External links

Nomenclature
HGNC (Hugo)MIR429   13784
Cards
AtlasMIR429ID51154ch1p36
Entrez_Gene (NCBI)MIR429  554210  microRNA 429
AliasesMIRN429; hsa-mir-429; mir-429
GeneCards (Weizmann)MIR429
Ensembl hg19 (Hinxton)ENSG00000198976 [Gene_View]  chr1:1104385-1104467 [Contig_View]  MIR429 [Vega]
Ensembl hg38 (Hinxton)ENSG00000198976 [Gene_View]  chr1:1104385-1104467 [Contig_View]  MIR429 [Vega]
ICGC DataPortalENSG00000198976
TCGA cBioPortalMIR429
AceView (NCBI)MIR429
Genatlas (Paris)MIR429
WikiGenes554210
SOURCE (Princeton)MIR429
Genetics Home Reference (NIH)MIR429
miRBaseMIR429
dbDEMCMIR429
Genomic and cartography
GoldenPath hg19 (UCSC)MIR429  -     chr1:1104385-1104467 +  1p36.33   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)MIR429  -     1p36.33   [Description]    (hg38-Dec_2013)
EnsemblMIR429 - 1p36.33 [CytoView hg19]  MIR429 - 1p36.33 [CytoView hg38]
Mapping of homologs : NCBIMIR429 [Mapview hg19]  MIR429 [Mapview hg38]
OMIM612094   
Gene and transcription
Genbank (Entrez)LM609019
RefSeq transcript (Entrez)
RefSeq genomic (Entrez)NC_000001 NC_018912 NT_032977 NW_004929288
Consensus coding sequences : CCDS (NCBI)MIR429
Alternative Splicing GalleryENSG00000198976
Gene ExpressionMIR429 [ NCBI-GEO ]   MIR429 [ EBI - ARRAY_EXPRESS ]   MIR429 [ SEEK ]   MIR429 [ MEM ]
Gene Expression Viewer (FireBrowse)MIR429 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
BioGPS (Tissue expression)554210
GTEX Portal (Tissue expression)MIR429
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)MIR429
DMDM Disease mutations554210
Blocks (Seattle)MIR429
Human Protein AtlasENSG00000198976
Protein Interaction databases
FunCoupENSG00000198976
BioGRIDMIR429
STRING (EMBL)MIR429
ZODIACMIR429
Ontologies - Pathways
Huge Navigator MIR429 [HugePedia]
snp3D : Map Gene to Disease554210
BioCentury BCIQMIR429
ClinGenMIR429
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD554210
Chemical/Pharm GKB GenePA164722713
Clinical trialMIR429
Miscellaneous
canSAR (ICR)MIR429 (select the gene name)
Probes
Litterature
PubMed37 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMIR429
EVEXMIR429
GoPubMedMIR429
iHOPMIR429
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:44:43 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.